Bradley Pharmaceuticals (BDY) Merges With Nycomed
Bradley Pharmaceuticals (NYSE: BDY) today announced it has reached a definitive merger agreement with Nycomed US Inc. Under the terms of the agreement, shares of Bradley will be converted into $20 per share in cash, a 25% premium from the closing price of $16 on October 29. The transaction implies a fully diluted equity value for Bradley of approximately $346 million.
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, develops and markets prescription and over-the-counter products in niche therapeutic markets, including dermatology, podiatry, gastroenterology and women’s health.
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, develops and markets prescription and over-the-counter products in niche therapeutic markets, including dermatology, podiatry, gastroenterology and women’s health.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- KKR (KKR) Said to Be in Talks with Delek Group for Phoenix Holdings Stake
- Dell (DELL) Could Be Considering Bid for Quest Software (QSFT)
Create E-mail Alert Related Categories
Hot List, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
